Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effect of Plant vs Animal Protein Supplementation on Body Composition in Youth Soccer Players (PLANT-ANIMAL-P)

2. Mai 2026 aktualisiert von: Antonio Molina Lopez

A Prospective, Single-Blind, Randomized Controlled Trial Comparing Plant-Based and Animal-Based Protein Supplementation Effects on Body Composition and Lean Mass in Elite Male Youth Soccer Players: A 4-Week Intervention Study

This prospective, single-blind, randomized controlled trial investigates the comparative effects of plant-based protein (soy and rice blend) versus animal-based protein (whey) supplementation on body composition parameters in elite male youth soccer players. Twenty-five players (ages 16-18.7 years) from Udinese Calcio's Primavera (U-19) category are randomized into three groups: Plant Protein Group (n=8), Animal Protein Group (n=9), and Placebo Group (n=8). The intervention consists of post-training protein supplementation (17g protein/dose) administered within 15-30 minutes after each training session over a 4-week microcycle during the competitive season. Body composition is assessed using a multi-compartmental model including anthropometry (ISAK protocol), bioelectrical impedance analysis (BIA), and dual-energy X-ray absorptiometry (DEXA).

Studienübersicht

Detaillierte Beschreibung

BACKGROUND AND RATIONALE Protein supplementation is widely used in elite sports to support muscle protein synthesis and recovery. While animal-based proteins (particularly whey) have traditionally been considered superior due to their complete amino acid profile, plant-based proteins have gained attention for ethical, environmental, and health reasons. However, limited evidence exists comparing their efficacy in elite youth athletes during competitive periods with high training loads. This study addresses this gap by comparing isocaloric, iso-nitrogenous plant-based and animal-based protein supplements on body composition in elite male youth soccer players during a 4-week competitive phase.

STUDY DESIGN Prospective, single-blind, randomized controlled trial with three parallel arms (1:1:1 allocation). Participants are unaware of group assignment and cannot identify supplement content due to identical packaging and delivery methods.

POPULATION Male youth soccer players (ages 16-18.7 years) from Udinese Calcio's Primavera (U-19) category during the 2025-2026 season, maintaining regular training schedules (minimum 4 sessions/week) combining technical-tactical field training and strength conditioning.

INTERVENTION

Participants are randomized to three groups:

  • Plant Protein Group (n=8): 330ml soy beverage + 22g plant protein powder = 17.4g total protein
  • Animal Protein Group (n=9): 200ml rice beverage + 33g whey protein (22g neutral + 11g vanilla) = 17.3g total protein
  • Placebo Group (n=8): 200ml rice beverage + vanilla flavoring = 0.2g total protein

Supplements are administered post-training (15-30 minutes) under direct nutrition staff supervision. Consumption is verified before participants leave the recovery area.

SUPPLEMENT PREPARATION Prepared 8 hours before consumption (09:00h) in individual labeled containers. Liquids measured with precision graduated containers, protein powder added via funnel (11g scoop). Containers manually shaken, refrigerated at 4°C, and re-shaken before consumption (17:00h).

BLINDING Single-blind design: participants unaware of three distinct groups; all containers and delivery identical. Nutrition staff aware of assignments (necessary for preparation and safety).

TRAINING CONTEXT Intervention occurs during competitive season with official matches every Saturday. Training microcycle features undulating workload with high-volume sessions (field + gym) on Tuesdays and Wednesdays. Following baseline assessment, players receive general nutritional guidelines but no strict dietary control (maintains ecological validity).

BODY COMPOSITION ASSESSMENT Multi-compartmental model maximizes precision. Participants maintain 8-hour fast and perform last urination 30 minutes before 07:00h assessment.

Assessment sequence:

  1. Bioelectrical Impedance Analysis (BIA 101 BIVA PRO): Verifies stable hydration via Bioelectrical Impedance Vector Analysis (BIVA)
  2. Anthropometry (ISAK protocol): International Society for Advancement of Kinanthropometry standardized restricted profile. Same certified evaluator performs all measurements on right body side:

    • 8 skinfolds: triceps, subscapular, biceps, iliac crest, supraspinal, abdominal, front thigh, medial calf
    • 3 circumferences: relaxed arm, mid-thigh, calf
    • Body fat via Faulkner formula: %FAT = [(triceps+subscapular+suprailiac+abdominal) × 0.153 + 5.783]
  3. Dual-Energy X-ray Absorptiometry (DEXA): Gold standard providing detailed fat mass, lean mass, bone mineral density, and regional distribution analysis

Assessment timeline: Baseline (Week 0) and Final (Week 4) with identical protocols.

STATISTICAL ANALYSIS Primary analysis: One-way ANOVA (or Kruskal-Wallis if non-normal) comparing mean fat-free mass changes between groups. Post-hoc tests (Bonferroni/Tukey HSD) for pairwise comparisons if significant. Secondary analyses use similar approaches. Intention-to-treat includes all randomized participants; per-protocol includes participants with ≥80% adherence. Baseline values, training load, and dietary intake may be covariates in ANCOVA models. Significance: α=0.05 (two-tailed).

SAMPLE SIZE N=25 (8-9 per group) based on feasibility given specialized population. This pilot study may detect moderate-large effects (Cohen's d≥0.6-0.8) using sensitive multi-compartmental methods.

SAFETY MONITORING Participants instructed to report adverse effects immediately. Regular check-ins during training, standardized adverse event documentation, classification by severity and relationship to intervention. Medical staff available during all sessions.

STUDY OBJECTIVES Primary: Compare effects of plant-based vs animal-based vs placebo protein supplementation on lean body mass changes in elite male youth soccer players over 4 weeks during competitive season.

Secondary: Compare effects on body fat percentage, total body mass, regional body composition, individual skinfold measurements, circumferences, adherence rates, and adverse events.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

25

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Udine
      • Udine, Udine, Italien, 33100
        • Udinese Calcio

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Active contract with Udinese Calcio's Primavera (U-19) category during the 2025-2026 season
  • Regular participation in the team's technical-tactical and strength training program (minimum 4 sessions per week)
  • Signed informed consent (parental consent for participants under 18 years)
  • Commitment to adhere to measurement protocol requiring 8-hour fast and assessment at 07:00h
  • Commitment to adhere to post-training supplementation protocol with administration at 17:00h
  • Confirmed presence and availability for both baseline assessment (Week 0) and final assessment (Week 4)

Exclusion Criteria:

  • Open injury records or currently in functional readaptation phase at study initiation
  • Consumption of ergogenic or nutritional supplementation independently and external to the club-supervised protocol during the 4 weeks prior to study or during the study period
  • Previous diagnosis or current symptomatology compatible with eating disorders
  • Known allergies or intolerances to soy, rice, dairy-based proteins, or vanilla flavoring
  • Current use of medications that may affect body composition or protein metabolism (anabolic steroids, growth hormone, corticosteroids, thyroid hormones)
  • Diagnosed chronic diseases that may affect protein metabolism or body composition (diabetes mellitus, chronic kidney disease, liver disease, malabsorption syndromes)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Plant Protein Group
Participants receive plant-based protein supplementation (17.4g protein per dose) consisting of 330ml soy beverage and 22g plant-based protein powder, administered within 15-30 minutes post-training under direct supervision for 4 weeks during competitive season.
Composition per dose: 330ml soy beverage (10.8g protein) + 22g plant protein powder (6.6g protein) = 17.4g total protein. Administered post-training (15-30 min after), prepared 8 hours before, stored at 4°C, supervised consumption verified by nutrition staff.
Andere Namen:
  • Soy protein
  • Plant protein blend
  • Vegetable protein
Aktiver Komparator: Animal Protein Group
Participants receive animal-based protein supplementation (17.3g protein per dose) consisting of 200ml rice beverage and 33g whey protein powder blend, administered within 15-30 minutes post-training under direct supervision for 4 weeks during competitive season.
Composition per dose: 200ml rice beverage (0.2g protein) + 22g neutral whey protein (12.0g protein) + 11g vanilla whey protein (5.1g protein) = 17.3g total protein. Administered post-training (15-30 min after), prepared 8 hours before, stored at 4°C, supervised consumption verified by nutrition staff.
Andere Namen:
  • Molkenprotein
  • Dairy protein
  • Milk protein
Placebo-Komparator: Placebo Group
Participants receive placebo supplementation (0.2g protein per dose) consisting of 200ml rice beverage and vanilla flavoring, administered within 15-30 minutes post-training under direct supervision for 4 weeks during competitive season. Appearance and delivery identical to active interventions.
Composition per dose: 200ml rice beverage (0.2g protein) + vanilla flavoring = 0.2g total protein. Administered post-training (15-30 min after), prepared 8 hours before, stored at 4°C, supervised consumption verified by nutrition staff. Identical appearance to active supplements to maintain blinding.
Andere Namen:
  • Placebo-Komparator
  • Kontrolle

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Fat-Free Mass (Lean Body Mass)
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Change in fat-free mass (kg) from baseline to week 4, assessed using a multi-compartmental model combining bioelectrical impedance analysis (BIA), anthropometry according to ISAK protocol, and dual-energy X-ray absorptiometry (DEXA). Fat-free mass represents total body mass minus fat mass.
Baseline (Week 0) and Final Assessment (Week 4)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Body Fat Percentage
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Change in body fat percentage from baseline to week 4, calculated using the Faulkner formula from skinfold measurements and validated by DEXA assessment. The Faulkner formula is: % FAT = (TR+SE+SI+AB) × 0.153 + 5.783, where TR=triceps, SE=subscapular, SI=suprailiac, AB=abdominal skinfolds in millimeters.
Baseline (Week 0) and Final Assessment (Week 4)
Change in Total Body Mass
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Change in total body weight (kg) from baseline to week 4.
Baseline (Week 0) and Final Assessment (Week 4)
Change in Total Lean Mass by DEXA
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Change in whole-body lean mass (kg) from baseline to week 4, assessed by dual-energy X-ray absorptiometry (DEXA) as a single composite measurement of total lean tissue.
Baseline (Week 0) and Final Assessment (Week 4)
Change in Sum of Skinfolds
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Change in sum of 8 skinfolds from baseline to week 4, measured according to ISAK protocol. The 8 individual skinfold measurements (triceps, subscapular, biceps, iliac crest, supraspinal, abdominal, front thigh, and medial calf in millimeters) will be summed to create a single aggregate value representing total subcutaneous adiposity. Results will be reported as mean change in total sum of skinfolds ± standard deviation.
Baseline (Week 0) and Final Assessment (Week 4)
Change in Limb Circumferences
Zeitfenster: Baseline (Week 0) and Final Assessment (Week 4)
Changes in circumference measurements from baseline to week 4, measured according to ISAK protocol. The 3 circumference measurements (relaxed arm, mid-thigh, and medial calf in centimeters) will be analyzed separately and reported as individual values for each site. Results will show mean change ± standard deviation for each circumference measurement independently.
Baseline (Week 0) and Final Assessment (Week 4)
Supplementation Adherence Rate
Zeitfenster: Throughout 4-week intervention period
Percentage of prescribed supplement doses consumed throughout the 4-week intervention period, calculated as (number of doses consumed / number of doses prescribed) × 100. Adherence is verified by direct observation and documentation by nutrition staff at each administration.
Throughout 4-week intervention period
Adverse Events
Zeitfenster: Throughout 4-week intervention period and 1 week post-intervention
Number and type of adverse events (gastrointestinal distress, allergic reactions, or any other adverse effects) related to supplement consumption.
Throughout 4-week intervention period and 1 week post-intervention

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Antonio Blas Molina Lopez, Phd, CTS-595 Research Group, Centre for Research into Physical and Sporting Performance. Universidad Pablo de Olavide

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. Januar 2026

Primärer Abschluss (Tatsächlich)

18. Februar 2026

Studienabschluss (Tatsächlich)

30. März 2026

Studienanmeldedaten

Zuerst eingereicht

8. März 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Mai 2026

Zuerst gepostet (Tatsächlich)

6. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

IPD-Sharing-Zeitrahmen

Individual participant data will be available immediately following publication of the primary manuscript and will remain available for at least 5 years. Supporting documents (study protocol and statistical analysis plan) will be available indefinitely.

IPD-Sharing-Zugriffskriterien

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal for academic purposes. Requests should be directed to the corresponding author at antoniomolina@centrosnutrifarma.es. Requestors will need to sign a data access agreement and specify the intended use of the data. Data will be provided in anonymized CSV format via secure file transfer within 30 days of approval.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren